European Commission Waives the Takeda’s Commitment to Obtain Clearance on Shire’s Acquisition

 European Commission Waives the Takeda’s Commitment to Obtain Clearance on Shire’s Acquisition

European Commission Waives the Takeda’s Commitment to Obtain Clearance on Shire’s Acquisition

Shots:

  • EC has released Takeda from the obligation to divest SHP647 & its associated rights. Takeda will discontinue the clinical study of SHP647 and will provide an opportunity to the participants to access in a PTA study
  • In 2018, EC approved its proposed acquisition of Shire with a condition. To avoid overlap in IBD b/w Takeda’s Entyvio (vedolizumab) and Shire’s SHP647, Takeda committed to divest SHP647 which became effective on Jan 08, 2019
  • Following the completion of the Shire acquisition, EC concluded that there is no competition concern b/w the drugs, thus Takeda’s obligation to divest SHP647 was no longer justified and the EC waived the commitment

Click here ­to­ read full press release/ article | Ref: Takeda | Image: Takeda